<DOC>
	<DOCNO>NCT03015675</DOCNO>
	<brief_summary>Linus Pauling Dr Ewan Cameron publish two retrospective study use high dose vitamin C treat cancer patient forty year ago . Their study show high dose vitamin C usage could significantly prolong overall survival patient advance cancer . Recently , preclinical study show human colorectal cancer cell harbor KRAS BRAF mutation selectively kill high level ascorbic acid ( AA ) . High dose AA impairs tumor growth Apc/KRASG12D mutant mouse . Previous phaseⅠclinical trial find high dose ( 1.5g/kg 90g/m2 ) iv AA well tolerate cancer patient . This protocol phase Ⅲ , study ascorbic acid ( AA ) infusion combine treatment mFOLOX6 versus mFOLOX6 alone first-line therapy patient recurrent advance gastric cancer .</brief_summary>
	<brief_title>IV Ascorbic Acid Advanced Gastric Cancer</brief_title>
	<detailed_description>Linus Pauling Dr Ewan Cameron publish two retrospective study use high dose vitamin C treat cancer patient forty year ago . Their study show high dose vitamin C usage could significantly prolong overall survival patient advance cancer . Recently , preclinical study show human colorectal cancer cell harbor KRAS BRAF mutation selectively kill high level ascorbic acid ( AA ) . High dose AA impairs tumor growth Apc/KRASG12D mutant mouse . Previous phaseⅠclinical trial find high dose ( 1.5g/kg 90g/m2 ) iv AA well tolerate cancer patient . This protocol phase Ⅲ , study ascorbic acid ( AA ) infusion combine treatment mFOLOX6 versus mFOLOX6 alone first-line therapy patient recurrent advance gastric cancer .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>Age≥18 year , ≤75 year ; Histologically prove metastatic adenocarcinoma stomach ( stage 4 disease ) , unresectable metastatic disease ; G6PD status &gt; low limit normal ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 ; Life expectancy least 12 week ; ANC ≥1,500/mm3 ; Hemoglobin &gt; 8g/dL ; platelet ≥ 100,000/mm3 ; Laboratory baseline evaluation inclusion study : creatinine ≤1.5X upper limit [ creatinine elevate , ≤1.5X ULN , 24 hour ; creatinine clearance obtain , Creatinine clearance &gt; 50 mL/min ( calculate accord Cockroft Gault ) ] ; Transaminase ( AST/ALT ) ≤2.5X upper limit normal bilirubin level ≤1.5X upper limit normal without liver metastasis ; Transaminase ( AST/ALT ) ≤5X upper limit normal bilirubin level ≤1.5X upper limit normal liver metastasis ; Women childbearing potential confirm negative pregnancy test must practice effective contraception study ; Written inform consent Prior treatment metastatic disease ( adjuvant therapy fluoropyrimidines +/oxaliplatin base regimen allow stop 12 month prior registration study ) ; Surgery ( exclude diagnostic biopsy ) irradiation within 3 week prior study entry ; Administration investigational drug agent/procedure , i.e . participation another trial within 4 week begin treatment ; Concurrent chronic systemic immune therapy , chemotherapy , radiation therapy ( palliative radiation therapy allow ) hormone therapy indicate study protocol ; Brain metastasis ( know suspect ) ; Pregnant lactate woman ; Other uncontrolled concomitant illness , include serious uncontrolled intercurrent infection ; Known allergy adverse reaction drug related compound ; Previous ( within 5 year ) concurrent malignancy sit exception surgically cure adequately treat carcinoma insitu cervix basal cell carcinoma skin ; Patients strong inducer CYP3A4 include limited : Aminoglutethimide , Bexarotene , Bosentan , Carbamazepine , Dexamethasone , Efavirenz , Fosphenytoin , Griseofulvin , Modafinil , Nafcillin , Nevirapine , Oxcarbazepine , Phenobarbital , Phenytoin , Primidone , Rifabutin , Rifampin , Rifapentine , St. John 's wort ; Medical , social psychological condition , opinion investigator , would permit patient complete study sign meaningful informed consent ; Organ allograft require immunosuppressive therapy ; Patients HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>